메뉴 건너뛰기




Volumn 6, Issue SUPPL. 1, 2011, Pages

Use of pharmacodynamic principles to inform β-lactam dosing: "S" does not always mean success

Author keywords

lactams; Meropenem; Monte Carlo simulation; Pharmacodynamics; Pharmacodynamics target attainment; Piperacillin tazobactam; Population pharmacokinetic modeling

Indexed keywords

CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; MONOBACTAM DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

EID: 78651075318     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.869     Document Type: Review
Times cited : (25)

References (38)
  • 1
    • 77955706083 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!
    • Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin Infect Dis. 2010; 51(Suppl 1): S103-S110.
    • (2010) Clin Infect Dis. , vol.51 , Issue.SUPPL. 1
    • Ambrose, P.G.1    Bhavnani, S.M.2    Ellis-Grosse, E.J.3    Drusano, G.L.4
  • 2
    • 33845696211 scopus 로고    scopus 로고
    • Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore
    • Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007; 44(1): 79-86.
    • (2007) Clin Infect Dis. , vol.44 , Issue.1 , pp. 79-86
    • Ambrose, P.G.1    Bhavnani, S.M.2    Rubino, C.M.3
  • 3
    • 0031952586 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men
    • -; quiz 11-12.
    • Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26(1): 1-10; quiz 11-12.
    • (1998) Clin Infect Dis. , vol.26 , Issue.1 , pp. 1-10
    • Craig, W.A.1
  • 4
    • 2142760947 scopus 로고    scopus 로고
    • Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
    • Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol. 2004; 2(4): 289-300.
    • (2004) Nat Rev Microbiol , vol.2 , Issue.4 , pp. 289-300
    • Drusano, G.L.1
  • 5
    • 77951761321 scopus 로고    scopus 로고
    • Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia
    • Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. Pharmacotherapy. 2010; 30(5): 453-462.
    • (2010) Pharmacotherapy , vol.30 , Issue.5 , pp. 453-462
    • Nicasio, A.M.1    Eagye, K.J.2    Kuti, E.L.3    Nicolau, D.P.4    Kuti, J.L.5
  • 6
    • 77049103406 scopus 로고    scopus 로고
    • Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia
    • Nicasio AM, Eagye KJ, Nicolau DP, et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care. 2010; 25(1): 69-77.
    • (2010) J Crit Care , vol.25 , Issue.1 , pp. 69-77
    • Nicasio, A.M.1    Eagye, K.J.2    Nicolau, D.P.3
  • 7
    • 33846153776 scopus 로고    scopus 로고
    • Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship
    • Dellit TH, Owens RC, McGowan JE, Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44(2): 159-177.
    • (2007) Clin Infect Dis. , vol.44 , Issue.2 , pp. 159-177
    • Dellit, T.H.1    Owens, R.C.2    McGowan Jr, J.E.3
  • 8
    • 28244501254 scopus 로고    scopus 로고
    • How modeling and simulation have enhanced decision making in new drug development
    • Miller R, Ewy W, Corrigan BW, et al. How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn. 2005; 32(2): 185-197.
    • (2005) J Pharmacokinet Pharmacodyn , vol.32 , Issue.2 , pp. 185-197
    • Miller, R.1    Ewy, W.2    Corrigan, B.W.3
  • 10
    • 78651108089 scopus 로고    scopus 로고
    • CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI document M100-S20. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2010.
    • CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI document M100-S20. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2010.
  • 11
    • 78651075183 scopus 로고    scopus 로고
    • Clinical and Laboratory Standards Institute/NCCLS. Performance standards for Antimicrobial disc diffusion tests; Approved standards. 9th ed. CLSI Document M2-M9. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
    • Clinical and Laboratory Standards Institute/NCCLS. Performance standards for Antimicrobial disc diffusion tests; Approved standards. 9th ed. CLSI Document M2-M9. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
  • 12
    • 33748092560 scopus 로고    scopus 로고
    • Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists
    • Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006; 26(9): 1320-1332.
    • (2006) Pharmacotherapy , vol.26 , Issue.9 , pp. 1320-1332
    • Lodise, T.P.1    Lomaestro, B.M.2    Drusano, G.L.3
  • 14
    • 0141924815 scopus 로고    scopus 로고
    • Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin
    • Odenholt I, Lowdin E, Cars O. Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin. Antimicrob Agents Chemother. 2003; 47(10): 3352-3356.
    • (2003) Antimicrob Agents Chemother. , vol.47 , Issue.10 , pp. 3352-3356
    • Odenholt, I.1    Lowdin, E.2    Cars, O.3
  • 15
    • 46249112774 scopus 로고    scopus 로고
    • In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci
    • Robertson GT, Bonventre EJ, Doyle TB, et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci. Antimicrob Agents Chemother. 2008; 52(7): 2324-2334.
    • (2008) Antimicrob Agents Chemother. , vol.52 , Issue.7 , pp. 2324-2334
    • Robertson, G.T.1    Bonventre, E.J.2    Doyle, T.B.3
  • 16
    • 0027221567 scopus 로고
    • The post-antibiotic sub-MIC effect in vitro and in vivo
    • Cars O, Odenholt-Tornqvist I. The post-antibiotic sub-MIC effect in vitro and in vivo. J Antimicrob Chemother. 1993; 31(Suppl D): 159-166.
    • (1993) J Antimicrob Chemother. , vol.31 , Issue.SUPPL. D , pp. 159-166
    • Cars, O.1    Odenholt-Tornqvist, I.2
  • 17
    • 0035178339 scopus 로고    scopus 로고
    • Pharmacodynamic effects of subinhibitory antibiotic concentrations
    • Odenholt I. Pharmacodynamic effects of subinhibitory antibiotic concentrations. Int J Antimicrob Agents. 2001; 17(1): 1-8.
    • (2001) Int J Antimicrob Agents , vol.17 , Issue.1 , pp. 1-8
    • Odenholt, I.1
  • 18
    • 0019480764 scopus 로고
    • Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes
    • McDonald PJ, Wetherall BL, Pruul H. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis. 1981; 3(1): 38-44.
    • (1981) Rev Infect Dis. , vol.3 , Issue.1 , pp. 38-44
    • McDonald, P.J.1    Wetherall, B.L.2    Pruul, H.3
  • 19
    • 0018592632 scopus 로고
    • Enhancement of leukocyte activity against Escherichia coli after brief exposure to chloramphenicol
    • Pruul H, McDonald PJ. Enhancement of leukocyte activity against Escherichia coli after brief exposure to chloramphenicol. Antimicrob Agents Chemother. 1979; 16(6): 695-700.
    • (1979) Antimicrob Agents Chemother. , vol.16 , Issue.6 , pp. 695-700
    • Pruul, H.1    McDonald, P.J.2
  • 20
    • 69249124938 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance
    • Adembri C, Novelli A. Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance. Clin Pharmacokinet. 2009; 48(8): 517-528.
    • (2009) Clin Pharmacokinet , vol.48 , Issue.8 , pp. 517-528
    • Adembri, C.1    Novelli, A.2
  • 21
    • 50549096398 scopus 로고    scopus 로고
    • Pharmacokinetics/pharmacodynamics of antibacterials in the intensive care unit: setting appropriate dosing regimens
    • Scaglione F, Paraboni L. Pharmacokinetics/pharmacodynamics of antibacterials in the intensive care unit: setting appropriate dosing regimens. Int J Antimicrob Agents. 2008; 32(4): 294-301.
    • (2008) Int J Antimicrob Agents , vol.32 , Issue.4 , pp. 294-301
    • Scaglione, F.1    Paraboni, L.2
  • 22
    • 0020665288 scopus 로고
    • Effect of protein binding on antibiotic activity in vivo
    • Merrikin DJ, Briant J, Rolinson GN. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother. 1983; 11(3): 233-238.
    • (1983) J Antimicrob Chemother. , vol.11 , Issue.3 , pp. 233-238
    • Merrikin, D.J.1    Briant, J.2    Rolinson, G.N.3
  • 23
    • 78651087864 scopus 로고    scopus 로고
    • Determining the active fraction of daptomycin against MRSA by evaluating bactericidal activity in the presence of protein and pharmacodynamic (PD) modeling
    • 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • Tsuji BT, Bulitta JB, Kelchlin PA, Holden PN, Forrest A. Determining the active fraction of daptomycin against MRSA by evaluating bactericidal activity in the presence of protein and pharmacodynamic (PD) modeling. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009; A1-1270.
    • (2009)
    • Tsuji, B.T.1    Bulitta, J.B.2    Kelchlin, P.A.3    Holden, P.N.4    Forrest, A.5
  • 24
    • 9644268224 scopus 로고    scopus 로고
    • Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation
    • Lodise TP, Jr., Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother. 2004; 48(12): 4718-4724.
    • (2004) Antimicrob Agents Chemother. , vol.48 , Issue.12 , pp. 4718-4724
    • Lodise Jr, T.P.1    Lomaestro, B.2    Rodvold, K.A.3    Danziger, L.H.4    Drusano, G.L.5
  • 25
    • 34347339333 scopus 로고    scopus 로고
    • Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment
    • DeRyke CA, Kuti JL, Nicolau DP. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis. 2007; 58(3): 337-344.
    • (2007) Diagn Microbiol Infect Dis. , vol.58 , Issue.3 , pp. 337-344
    • DeRyke, C.A.1    Kuti, J.L.2    Nicolau, D.P.3
  • 26
    • 40749099832 scopus 로고    scopus 로고
    • Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint
    • Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 15 2008; 46(6): 862-867.
    • (2008) Clin Infect Dis. 15 , vol.46 , Issue.6 , pp. 862-867
    • Tam, V.H.1    Gamez, E.A.2    Weston, J.S.3
  • 27
    • 33846442436 scopus 로고    scopus 로고
    • Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy
    • Lodise TP, Jr., Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 1 2007; 44(3): 357-363.
    • (2007) Clin Infect Dis. 1 , vol.44 , Issue.3 , pp. 357-363
    • Lodise Jr, T.P.1    Lomaestro, B.2    Drusano, G.L.3
  • 28
    • 0029988372 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
    • Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 1996; 15(3): 255-259.
    • (1996) Pediatr Infect Dis J. , vol.15 , Issue.3 , pp. 255-259
    • Craig, W.A.1    Andes, D.2
  • 29
    • 0029097440 scopus 로고
    • Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
    • Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995; 22(1-2): 89-96.
    • (1995) Diagn Microbiol Infect Dis. , vol.22 , Issue.1-2 , pp. 89-96
    • Craig, W.A.1
  • 30
    • 12844252430 scopus 로고    scopus 로고
    • How does a patient maximally benefit from anti-infective chemotherapy?
    • Drusano GL. How does a patient maximally benefit from anti-infective chemotherapy? Clin Infect Dis. 2004; 39(8): 1245-1246.
    • (2004) Clin Infect Dis. , vol.39 , Issue.8 , pp. 1245-1246
    • Drusano, G.L.1
  • 31
    • 35848946597 scopus 로고    scopus 로고
    • Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
    • Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy. 2007; 27(11): 1490-1497.
    • (2007) Pharmacotherapy , vol.27 , Issue.11 , pp. 1490-1497
    • Kim, A.1    Sutherland, C.A.2    Kuti, J.L.3    Nicolau, D.P.4
  • 32
    • 66449092115 scopus 로고    scopus 로고
    • A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics
    • Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med. 2009; 37(6): 2071-2078.
    • (2009) Crit Care Med. , vol.37 , Issue.6 , pp. 2071-2078
    • Roberts, J.A.1    Webb, S.2    Paterson, D.3    Ho, K.M.4    Lipman, J.5
  • 33
    • 1242315414 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients
    • Mohr JF, Wanger A, Rex JH. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis. 2004; 48(2): 125-130.
    • (2004) Diagn Microbiol Infect Dis. , vol.48 , Issue.2 , pp. 125-130
    • Mohr, J.F.1    Wanger, A.2    Rex, J.H.3
  • 34
    • 16244414846 scopus 로고    scopus 로고
    • Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment
    • Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005; 49(4): 1306-1311.
    • (2005) Antimicrob Agents Chemother. , vol.49 , Issue.4 , pp. 1306-1311
    • Micek, S.T.1    Lloyd, A.E.2    Ritchie, D.J.3
  • 35
    • 3342962524 scopus 로고    scopus 로고
    • Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)
    • Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents. 2004; 24(2): 111-118.
    • (2004) Int J Antimicrob Agents , vol.24 , Issue.2 , pp. 111-118
    • Streit, J.M.1    Jones, R.N.2    Sader, H.S.3    Fritsche, T.R.4
  • 36
    • 9144238410 scopus 로고    scopus 로고
    • Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres
    • Rhomberg PR, Jones RN, Sader HS. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres. Int J Antimicrob Agents. 2004; 23(1): 52-59.
    • (2004) Int J Antimicrob Agents , vol.23 , Issue.1 , pp. 52-59
    • Rhomberg, P.R.1    Jones, R.N.2    Sader, H.S.3
  • 37
    • 78651081377 scopus 로고    scopus 로고
    • Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America. Washington DC, Abstr 1889.
    • Lodise TP, Sorgel F, Mason B, et al. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America. Washington DC, 2008. Abstr 1889.
    • (2008)
    • Lodise, T.P.1    Sorgel, F.2    Mason, B.3
  • 38
    • 28844443170 scopus 로고    scopus 로고
    • Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa
    • In press.
    • Tam VH, Schilling AN, Neshat S, et al. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. In press.
    • Antimicrob Agents Chemother
    • Tam, V.H.1    Schilling, A.N.2    Neshat, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.